Breast Neoplasm Clinical Trial
— F-ChemOfficial title:
Effects of Music or Hypnotherapy on Cancer Patients During Chemotherapy - A Prospective Off-centre Randomized Placebo-controlled Trial
Verified date | November 2021 |
Source | Dr. Horst Schmidt Klinik GmbH |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chemotherapies often induce side effects. This study examines whether hypnosis, music therapy versus standard therapy influence these side effects.
Status | Terminated |
Enrollment | 81 |
Est. completion date | November 1, 2021 |
Est. primary completion date | November 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - no previous chemotherapy - compliance of the patient to fill out questionnaires - informed consent and signed forms - histologic secured breast cancer or ovary cancer (residual tumor after surgery equal or less than 0,5 cm) - One of following chemotherapy regime: 4x Epirubicin / Cyclophosphamid, 12x paclitaxel oder 6x Carboplatin / Docetaxel / Perjeta/ Herceptin oder 6x Doxorubicin, docetaxel, Cyclophosphamid oder 6 x Carboplatin / paclitaxel + / - Avastin oder 4x Epirubicin / Cyclophosphamid -> 12x paclitaxel /herceptin/ perjeta oder 4x Epirubicin / Cyclophosphamid q21->12xcarboplatin, paclitaxel 4 Epirubicin / Cyclophosphamid q14-> 12 carboplatin, paclitaxel Exclusion Criteria: - does not understand the German language - psychosis - not able to sign consent form |
Country | Name | City | State |
---|---|---|---|
Germany | Helios Berlin Buch | Berlin | |
Germany | Helios Kliniken Schwerin GmbH | Schwerin | |
Germany | Klinik für Gynäkologie und gynäkologischen Onkologie | Wiesbaden | Hessen |
Lead Sponsor | Collaborator |
---|---|
Dr. Horst Schmidt Klinik GmbH | Deutsche Gesellschaft für hypnose und hypnotherapie E.V. |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ZSDS = Zung Self-rating Depression Scale | Change of questionnaire scores | Every three weeks during chemotherapy and one year after last chemotherapy | |
Primary | Quality of life questionnaire - Core30 | Change of questionnaire scores | Every three weeks during chemotherapy and one year after last chemotherapy | |
Primary | Patient diary, number of emetic episodes, the intensity of Nausea and QoL evaluation (functional living index-emesis questionnaire) | Change of questionnaire scores | Day 1-5 after chemotherapie and before next chemotherapy | |
Primary | Fatigue assessment questionnaire (FAQ) | Change of questionnaire scores | Every three weeks during chemotherapy and one year after last chemotherapy | |
Primary | Screening Scale for Taste Alteration (TA) | Change of questionnaire scores | Every three weeks during chemotherapy and one year after last chemotherapy | |
Secondary | Change of heart rate | Long term ECG recording before and during chemotherapy | change of average heart rate after 5 minutes rest, 5 minutes before chemotherapy and 5 minutes into chemotherapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03273426 -
Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.
|
N/A | |
Recruiting |
NCT04583124 -
Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO)
|
N/A | |
Active, not recruiting |
NCT04489173 -
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT02913573 -
Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction
|
Phase 2 | |
Completed |
NCT03124095 -
Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer
|
N/A | |
Terminated |
NCT00251095 -
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT05576545 -
Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment
|
N/A | |
Active, not recruiting |
NCT03625635 -
Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment
|
N/A | |
Recruiting |
NCT04799535 -
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
|
||
Withdrawn |
NCT03266562 -
Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography
|
N/A | |
Completed |
NCT00530868 -
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
|
Phase 2 | |
Recruiting |
NCT06255808 -
Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
|
||
Completed |
NCT04640220 -
Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors
|
N/A | |
Completed |
NCT02970682 -
SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT02316561 -
Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer
|
N/A | |
Terminated |
NCT00638963 -
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
|
Phase 2 | |
Terminated |
NCT00249301 -
A Study of MLN8054 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06056414 -
Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation
|
N/A | |
Recruiting |
NCT05427071 -
Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy
|
N/A | |
Recruiting |
NCT03740893 -
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
|
Phase 2 |